Motif Bio plc – grant of share options to PDMR

18 January 2017

Grant of share options to PDMR

Motif Bio plc
(“Motif Bio” or the “Company”)

Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces that the Company has granted a total of 1,500,000 options to purchase ordinary shares of 1 pence each of Motif Bio (“Ordinary Shares”) to Robert Dickey IV, Chief Financial Officer. The options vest over a four year period and have an exercise price of 25.5 pence per Ordinary Share, being the closing price of the Ordinary Shares on 17 January 2017, the date of grant of the options.

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

1 Details of the person discharging managerial responsibilities/person closely associated
a) Name Robert Dickey IV
2 Reason for the notification
a) Position/status Chief Financial Officer, PDMR
b) Initial notification/Amendment Initial Notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name Motif Bio Plc
b) LEI 54930080DN00QTIUUU84
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument

Identification code

Ordinary Shares



b) Nature of the transaction Grant of options to purchase 1,500,000 Ordinary Shares
c) Price(s) and volume(s)


Price(s) Volume(s)
N/A 1,500,000
d) Aggregated information


Price(s) Volume(s)
N/A 1,500,000
e) Date of the transaction 17 January 2017
f) Place of the transaction N/A


For further information please contact:
Motif Bio plc
Graham Lumsden (Chief Executive Officer):

Zeus Capital Limited (NOMAD & BROKER)
Phil Walker/Giles Balleny/Dominic Wilson: +44 (0)20 3829 5000

Northland Capital Partners Limited (BROKER)
Patrick Claridge/David Hignell/John Howes/Rob Rees: +44 (0)20 7382 1100

Walbrook PR Ltd. (FINANCIAL PR & IR): +44 (0)20 7933 8780 or
Paul McManus Mob: +44 (0)7980 541 893
Mike Wort Mob: +44 (0)7900 608 002

Raimund Gabriel: +49 (0)89 210 2280

Notes to Editors
Motif Bio is a clinical-stage biopharmaceutical company, engaged in the research and development of novel antibiotics designed to be effective against serious and life-threatening infections in hospitalised patients caused by multi-drug resistant bacteria. Our lead product candidate, iclaprim, is being developed for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including ventilator associated bacterial pneumonia (VABP), which is often caused by MRSA (methicillin resistant Staphylococcus aureus). We are currently enrolling and dosing patients in two global Phase 3 clinical trials (Revive 1 and Revive 2) with an intravenous formulation of iclaprim, for the treatment of ABSSSI. Data readout for REVIVE-1 is expected in the second quarter of 2017 and REVIVE-2 is on track for data readout in the second half of 2017.

This information is provided by RNS
The company news service from the London Stock Exchange